Abstract
Genetic, immune and environmental interactions are key elements for the development of COPD. Cigarette smoking is considered the primary risk factor initiating inflammatory cascades in genetically susceptible individuals.
The “danger signals” elicited by the injured cells of non-specific immunity induce the downstream activation of proinflammatory cascades and antigen-specific adaptive immune responses. The produced oxidative stress further damages the lung leading to acquired genetic changes (histone deacetylation, microsatellite DNA instability, DNA methylation, telomere shortening, miRNA alterations) due to an inefficient DNA repair machinery. On the other hand, augmented apoptosis, impaired efferocytosis and abnormal tissue remodeling contribute to the chronic inflammatory response and tissue destruction in COPD.
This review focuses on the role of genetic, epigenetic and immune mechanisms in the development of COPD in order to put forward possible prognostic and therapeutic targets.
Keywords: Adaptive immunity, chronic inflammation, chronic obstructive pulmonary disease, DNA damage, epigenetics, innate immunity, oxidative stress
Current Drug Targets
Title:Immune and Genetic Mechanisms in COPD: Possible Targets for Therapeutic Interventions
Volume: 14 Issue: 2
Author(s): Eleni G. Tzortzaki, Alberto Papi, Eirini Neofytou, Nikolaos Soulitzis and Nikolaos M. Siafakas
Affiliation:
Keywords: Adaptive immunity, chronic inflammation, chronic obstructive pulmonary disease, DNA damage, epigenetics, innate immunity, oxidative stress
Abstract: Genetic, immune and environmental interactions are key elements for the development of COPD. Cigarette smoking is considered the primary risk factor initiating inflammatory cascades in genetically susceptible individuals.
The “danger signals” elicited by the injured cells of non-specific immunity induce the downstream activation of proinflammatory cascades and antigen-specific adaptive immune responses. The produced oxidative stress further damages the lung leading to acquired genetic changes (histone deacetylation, microsatellite DNA instability, DNA methylation, telomere shortening, miRNA alterations) due to an inefficient DNA repair machinery. On the other hand, augmented apoptosis, impaired efferocytosis and abnormal tissue remodeling contribute to the chronic inflammatory response and tissue destruction in COPD.
This review focuses on the role of genetic, epigenetic and immune mechanisms in the development of COPD in order to put forward possible prognostic and therapeutic targets.
Export Options
About this article
Cite this article as:
G. Tzortzaki Eleni, Papi Alberto, Neofytou Eirini, Soulitzis Nikolaos and M. Siafakas Nikolaos, Immune and Genetic Mechanisms in COPD: Possible Targets for Therapeutic Interventions, Current Drug Targets 2013; 14 (2) . https://dx.doi.org/10.2174/1389450111314020002
DOI https://dx.doi.org/10.2174/1389450111314020002 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structure, Function and Inhibition of Bcl-2 Family Proteins: A New Target for Anti-Tumor Agents
Mini-Reviews in Medicinal Chemistry Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design Anti-cancer Nitrogen-Containing Heterocyclic Compounds
Current Organic Chemistry Self-Assembled Micelles of Amphiphilic PEGylated Drugs for Cancer Treatment
Current Drug Targets Interactive Effect of Combined Exposure to Active and Passive Smoking on Cardiovascular System
Recent Patents on Cardiovascular Drug Discovery Subject Index To Volune 2
Current Cancer Therapy Reviews Cancer Chemotherapy by Novel Bio-active Natural Products: Looking Towards the Future
Current Cancer Therapy Reviews Past, Present, and Future of Targeting Ras for Cancer Therapies
Mini-Reviews in Medicinal Chemistry Development of Molecular Targeted Anticancer Agents: Successes, Failures and Future Directions
Current Pharmaceutical Design Personalized Medicine for Glioblastoma: Current Challenges and Future Opportunities
Current Molecular Medicine Prediction and Early Evaluation of Anticancer Therapy Response: From Imaging of Drug Efflux Pumps to Targeted Therapy Response
Current Medicinal Chemistry Bleomycin and its Role in Inducing Apoptosis and Senescence in Lung Cells - Modulating Effects of Caveolin-1
Current Cancer Drug Targets Design, Synthesis and Biological Evaluation of Some Novel Thiazole-2- Carboxamide Derivatives as Antitumor Agents
Letters in Drug Design & Discovery Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewing’s Sarcoma Tumor Cells
Current Pharmaceutical Biotechnology MicroRNAs and Cancer Therapy – From Bystanders to Major Players
Current Medicinal Chemistry Advances in Liver-Directed Gene Therapy for Hepatocellular Carcinoma by Non-Viral Delivery Systems
Current Gene Therapy The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Hedgehog Signaling and Urological Cancers
Current Drug Targets Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design